Apixaban: Low-Dose Long-Term Use After Provoked VTE Shows Benefits
Christopher Cannon, Editor in Chief, Harvard Health Publishing, shared a post on LinkedIn:
“Low-dose Apixaban long-term following a “provoked” VTE is beneficial.
I think that practice will change – from stopping anticoagulation after a period of initial treatment, to reducing to 1/2 dose for long-term prevention.
This has been my practice for “unprovoked” DVT/PE based on a host of other trials, but this study now extends this: it looked at those with a transient factor like surgery, trauma or immobility – but with an enduring risk factor: ASCVD, Obesity, Heart failure (systolic, diastolic, or combined, lung disease(COPD, asthma, interstitial lung disease), Chronic kidney disease (eGFR <60 mL/min/1.72m2)
Chronic inflammatory/autoimmune disorder (inflammatory arthritis, vasculitis, inflammatory bowel disease, chronic infection) or Persistent immobility. That covers a lot of patients.
Younger, healthy patients who have “provoked” VTE. e.g., post surgery or immobility- they would be ones where stopping after an initial period of anticoagulation is reasonable.
Congratulations Gregory Piazza, Samuel Z. Goldhaber, MD and colleagues!”
Read full article here.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25